AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1610576 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine premedication
Number of subjects: 49
Study 6148881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 to 320 mg for 6 weeks)
Number of subjects: 8
Study 31517543 — intervention group
Group type: EXPERIMENTAL
Intervention: Child STEPs treatment program
Number of subjects: 156
Study 31517543 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 156
Study 30845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Number of subjects: 28000
Study 30845320 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal serogroup A conjugate vaccine (control)
Number of subjects: 28000
Study 29524194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Se diet (−Se group, 0.033 mg/kg Se)
Number of subjects: 120
Study 29524194 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control group, 0.2 mg/kg Se)
Number of subjects: 120
Study 27965256 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 42
Study 27965256 — intervention group
Group type: COMPARATOR
Intervention: Minimal acupuncture
Number of subjects: 42
Study 24652419 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 40
Study 24652419 — intervention group
Group type: COMPARATOR
Intervention: Reverse Distal Femoral Locking Compression Plate (reverse-DFLCP)
Number of subjects: 40
Study 22688598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 80
Study 22688598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19173706 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 SNPs at the 9p21 locus
Number of subjects: 332
Study 17159195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 6 months)
Number of subjects: 401
Study 17159195 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy without zoledronic acid
Number of subjects: 401
Study 17159195 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole/goserelin
Number of subjects: 401
Study 17159195 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen/goserelin
Number of subjects: 401
Study 16371734 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography +/‐ endoscopic sphincterotomy (ERCP +/‐ ES) within 48 hours
Number of subjects: 61
Study 16371734 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment and selective ERCP +/‐ ES after 48 hours
Number of subjects: 61
Study 12783774 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet (NF) containing 39% energy as fat
Number of subjects: 9
Study 12783774 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich athlete's diet (LF) containing 24% energy as fat
Number of subjects: 9
Study 12783774 — intervention group
Group type: EXPERIMENTAL
Intervention: During exercise
Number of subjects: 9
Study 12783774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence microscopy
Number of subjects: 9
Study 10632835 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 11
Study 10632835 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 11
Study 10632835 — intervention group
Group type: COMPARATOR
Intervention: Warfarin vs Aspirin
Number of subjects: 11
Study 9239866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 31
Study 9239866 — intervention group
Group type: COMPARATOR
Intervention: Casual blood pressure measurement
Number of subjects: 31
Study 9239866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure average values for two or 24 hours
Number of subjects: 31
Study 9239866 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Number of subjects: 31
Study 1295122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (Nidrel 20 mg) administered once daily in the morning
Number of subjects: 41
Study 1295122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (Nidrel 20 mg) administered once daily in the evening
Number of subjects: 41
Study 1295122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (Nidrel 20 mg) administered once daily (both morning and evening)
Number of subjects: 41
Study 6203228 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (decaris) as an interferon inducer
Number of subjects: 74
Study 6203228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no levamisole)
Number of subjects: 74
Study 6203228 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (decaris)
Number of subjects: 74
Study 6203228 — intervention group
Group type: COMPARATOR
Intervention: Severe forms of influenza (control group)
Number of subjects: 74
Study 31790484 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on training program involving breathing exercises, cold exposure, and meditation
Number of subjects: 24
Study 31790484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 29458218 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids plus piperine (500 mg/day curcuminoids and 5 mg/day piperine)
Number of subjects: 100
Study 29458218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BP
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MSNA
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up BP
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up MSNA
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SBP and DBP at baseline
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SBP and DBP at follow-up
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: MSNA tracking correlation
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MSNA and DBP at baseline
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MSNA and DBP at follow-up
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI change at follow-up
Number of subjects: 13
Study 26654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic responses to handgrip and mental stressors
Number of subjects: 13
Study 24121756 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 75 mg bid
Number of subjects: 33
Study 24121756 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 150 mg bid
Number of subjects: 33
Study 24121756 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg bid
Number of subjects: 33
Study 24121756 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg qd
Number of subjects: 33
Study 23145859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam 500 mg plus avibactam 125 mg every 8 hours for 7-14 days
Number of subjects: 135
Study 23145859 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin 500 mg every 6 hours for 7-14 days
Number of subjects: 135
Study 23145859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 135
Study 23145859 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 135
Study 21030934 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) for secondary prevention
Number of subjects: 0
Study 21030934 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) for primary prevention
Number of subjects: 0
Study 21030934 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging data on ASA efficacy and safety
Number of subjects: 0
Study 21030934 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to enhance safety and efficacy of ASA
Number of subjects: 0
Study 21030934 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of ASA prescription
Number of subjects: 0
Study 18572751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg/day
Number of subjects: 0
Study 16038683 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 536
Study 16038683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 12718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to human wastes (occupational groups)
Number of subjects: 519
Study 12718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of drinking water from New Zealand supplies other than metropolitan mains supplies
Number of subjects: 519
Study 12718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of drinking water from sources outside New Zealand
Number of subjects: 519
Study 12718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveling
Number of subjects: 519
Study 12718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming in pools or fresh water at least once a week
Number of subjects: 519
Study 10811525 — intervention group
Group type: EXPERIMENTAL
Intervention: CYCLO 3 FORT
Number of subjects: 80
Study 10811525 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl rutoside (rutoside)
Number of subjects: 80
Study 8526578 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair (stainless steel or polypropylene)
Number of subjects: 1578
Study 8526578 — intervention group
Group type: COMPARATOR
Intervention: Bassini's repair
Number of subjects: 1578
Study 8526578 — intervention group
Group type: COMPARATOR
Intervention: Cooper's ligament repair
Number of subjects: 1578
Study 8526578 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair (stainless steel)
Number of subjects: 1578
Study 8526578 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair (polypropylene)
Number of subjects: 1578
Study 2044551 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U intravenous injection over 2-5 minutes)
Number of subjects: 116
Study 2044551 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1,500,000 U intravenous infusion over 60 minutes)
Number of subjects: 116
Study 2044551 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 116
Study 2044551 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 116
Study 7025638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg, 5 mg every 12 hours, intramuscularly)
Number of subjects: 696
Study 7025638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 7025638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 696
Study 31208259 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Digital Storytelling Intervention (EDSI)
Number of subjects: 98
Study 31208259 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 98
Study 29129737 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PUFA diet (low-fat high-carbohydrate diet enriched in n-3 PUFA)
Number of subjects: 20
Study 29129737 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PUFA meal
Number of subjects: 20
Study 29129737 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet enriched in MUFA with virgin olive oil
Number of subjects: 20
Study 29129737 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich diet
Number of subjects: 20
Study 27916480 — intervention group
Group type: EXPERIMENTAL
Intervention: A1 proteinase inhibitor (A1PI) treatment (60 mg/kg per week)
Number of subjects: 140
Study 27916480 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start group (placebo)
Number of subjects: 140
Study 27916480 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start group (after 24 months)
Number of subjects: 140
Study 27916480 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start group (after 24 months)
Number of subjects: 140
Study 25408261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomelo pulp (250g)
Number of subjects: 0
Study 25408261 — intervention group
Group type: COMPARATOR
Intervention: Water (250mL)
Number of subjects: 0
Study 24627921 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted intravenous fluid regimen (R group)
Number of subjects: 174
Study 24627921 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid regimen (S group)
Number of subjects: 174
Study 20933512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavonol diet
Number of subjects: 17
Study 20933512 — intervention group
Group type: COMPARATOR
Intervention: Low-flavonol diet
Number of subjects: 17
Study 18182544 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 92
Study 18182544 — intervention group
Group type: COMPARATOR
Intervention: Conventional vocational rehabilitation program
Number of subjects: 92
Study 16645442 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at the rate of 1-8 mug . kg . min for 15-20 min
Number of subjects: 28
Study 16645442 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate entropy (ApEn)
Number of subjects: 28
Study 16645442 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal montages
Number of subjects: 28
Study 12965108 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg t.i.d. for 16 weeks
Number of subjects: 100
Study 12965108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10907674 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 44
Study 10907674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 100 mg)
Number of subjects: 44
Study 8836952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg melatonin
Number of subjects: 32
Study 8836952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin
Number of subjects: 32
Study 8836952 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg melatonin
Number of subjects: 32
Study 8836952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg melatonin
Number of subjects: 32
Study 8836952 — intervention group
Group type: COMPARATOR
Intervention: sucrose placebo
Number of subjects: 32
Study 1317939 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/min human alpha atrial natriuretic factor (h alpha ANF)
Number of subjects: 6
Study 1317939 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 1317939 — intervention group
Group type: COMPARATOR
Intervention: 3 IU AVP
Number of subjects: 6
Study 6438674 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (Valium) administration
Number of subjects: 0
Study 6438674 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31484076 — intervention group
Group type: EXPERIMENTAL
Intervention: β-glucan trained monocytes
Number of subjects: 0
Study 31484076 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 31484076 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-32 expression
Number of subjects: 0
Study 29469177 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion (24 hours)
Number of subjects: 23
Study 26500107 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (calfactant/Infasurf)
Number of subjects: 511
Study 26500107 — intervention group
Group type: COMPARATOR
Intervention: Sham instillation
Number of subjects: 511
Study 24758641 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed oocyte maturation trigger (24 hours later) in patients with low progesterone (<= 1 ng/ml)
Number of subjects: 131
Study 24758641 — intervention group
Group type: COMPARATOR
Intervention: Control group (same day trigger) in patients with low progesterone (<= 1 ng/ml)
Number of subjects: 131
Study 24758641 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed oocyte maturation trigger (24 hours later) in patients with elevated progesterone (> 1 ng/ml)
Number of subjects: 131
Study 24758641 — intervention group
Group type: COMPARATOR
Intervention: Control group (same day trigger) in patients with elevated progesterone (> 1 ng/ml)
Number of subjects: 131
Study 23460253 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 289
Study 23460253 — intervention group
Group type: EXPERIMENTAL
Intervention: Film dressing
Number of subjects: 289
Study 23460253 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 289
Study 20435234 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg
Number of subjects: 131
Study 20435234 — intervention group
Group type: COMPARATOR
Intervention: Entecavir 0.5 mg
Number of subjects: 131
Study 19040944 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict definition of perforation (a hole in the appendix or a fecalith in the abdomen)
Number of subjects: 131
Study 19040944 — intervention group
Group type: COMPARATOR
Intervention: Nonperforated appendicitis (treated as nonperforated)
Number of subjects: 131
Study 16630123 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent R-CHOP (6 courses of CHOP concurrently with rituximab)
Number of subjects: 69
Study 16630123 — intervention group
Group type: COMPARATOR
Intervention: Sequential R-CHOP (6 courses of CHOP followed by 6 courses of weekly rituximab)
Number of subjects: 69
Study 14649479 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of minimal residual disease (MRD) by identifying clone-specific T-cell receptor (TCR) or immunoglobulin (Ig) gene rearrangements
Number of subjects: 0
Study 14649479 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of residual disease at defined timepoints by cytomorphology
Number of subjects: 0
Study 14649479 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized tools for treatment response evaluation
Number of subjects: 0
Study 11298086 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg)
Number of subjects: 22
Study 11298086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9674365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood screening
Number of subjects: 0
Study 9674365 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of benign polyps larger than 9 mm
Number of subjects: 0
Study 9674365 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy
Number of subjects: 0
Study 7939995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrel-Dubousset instrumentation (CDI) with instrumentation/fusion of the proximal thoracic curve up to T2 in Group I patients.
Number of subjects: 54
Study 7939995 — intervention group
Group type: COMPARATOR
Intervention: Cotrel-Dubousset instrumentation (CDI) without instrumentation/fusion of the upper thoracic curve in Group II patients.
Number of subjects: 54
Study 3283229 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium intake (1400 mg/day: 400‐mg calcium diet plus two 500‐mg calcium tablets/day)
Number of subjects: 15
Study 3283229 — intervention group
Group type: COMPARATOR
Intervention: Low calcium intake (400 mg calcium diet plus two placebo tablets/day)
Number of subjects: 15
Study 3283229 — intervention group
Group type: COMPARATOR
Intervention: Low calcium intake
Number of subjects: 15
Study 3283229 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium intake
Number of subjects: 15
Study 31436886 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily naltrexone
Number of subjects: 86
Study 31436886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 27340247 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 456
Study 26351344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus capecitabine
Number of subjects: 127
Study 26351344 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus capecitabine
Number of subjects: 127
Study 26351344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus capecitabine (in patients with inflammation)
Number of subjects: 127
Study 26351344 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus capecitabine (in patients with inflammation)
Number of subjects: 127
Study 23369075 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (supervised exercise training twice weekly for eight weeks)
Number of subjects: 116
Study 23369075 — intervention group
Group type: COMPARATOR
Intervention: Usual care (weekly telephone support)
Number of subjects: 116
Study 23369075 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 116
Study 21815740 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive message framing
Number of subjects: 188
Study 21815740 — intervention group
Group type: COMPARATOR
Intervention: Negative message framing
Number of subjects: 188
Study 19168349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500mg/m² (Pem500)
Number of subjects: 102
Study 19168349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 900mg/m² (Pem900)
Number of subjects: 102
Study 16461201 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 812
Study 16461201 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg
Number of subjects: 812
Study 15291653 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of fluvoxamine (50 mg/day) plus low-dose clozapine (≤ 250 mg/day)
Number of subjects: 68
Study 15291653 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with clozapine (≤ 600 mg/day)
Number of subjects: 68
Study 11412167 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 22
Study 11412167 — intervention group
Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 22
Study 9415855 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress (mental arithmetic)
Number of subjects: 75
Study 9415855 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 75
Study 9415855 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 75
Study 8429114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg, four times daily)
Number of subjects: 10